SCORE2, like SCORE, performs well in categorizing patients with events as medium- or high risk when compared to PROCAM. Additional information regarding calibration and discrimination of SCORE2 compared to PROCAM and SCORE was small. The addition of the TPA-Bayes criterion to SCORE2 as well as TPA itself outperformed risk models without incorporation of TPA regarding MACE and ASCVD. TPA contains important clinical information beyond SCORE2 and should be used jointly in order to allocate preventive resources as soon and as personalised as possible.
References
Romanens M., Adams A., Sudano I., et al. Prediction of cardiovascular events with traditional risk equations and total plaque area of carotid atherosclerosis. Preventive Medicine 2021;147:106525.
Romanens M., Adams A., Bojara W., Balint S., Warmuth W. Cost-Effectiveness-Analysis of Statins in primary care. Results from the Arteris Cohort Study. smw.ch/article/doi/smw.2021.20498